US EditionKodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
- Kodiak Sciences Inc. Announced the completion of enrollment in the GLOW2 Phase 3 trial for tarcocimab in diabetic retinopathy patients.
- The study design of GLOW2 mirrors the successful GLOW1 study, which met its primary endpoint with high statistical significance.
- Dr. Victor Perlroth stated that topline clinical data is expected to be announced in the first quarter of 2026 after all patients complete visits by January 2026.
- Dr. Hu emphasized that tarcocimab could change the treatment landscape for diabetic retinopathy, helping millions of patients with its less frequent dosing.
Insights by Ground AI
Does this summary seem wrong?
24 Articles
24 Articles
All
Left
1
Center
10
Right
Helena Independent Record+22 Reposted by 22 other sources
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026.GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance
·Helena, United States
Read Full Article
Coverage Details
Total News Sources24
Leaning Left1Leaning Right0Center10Last UpdatedBias Distribution91% Center
Bias Distribution
- 91% of the sources are Center
91% Center
C 91%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage